BRAF and non-small cell lung carcinoma: Likewise, it has been found that the newer targeted therapy, including inhibitors of EGFR, ALK, PI3K/AKT/mTOR, RAS-MAPK, RET, MET, BRAF, and NTRK/ROS1, as well as PD1 and CTLA4 molecules, for non-small cell lung cancer (NSCLC) have far better treatment responses than the standard therapies (35).